Vincerx Pharma Inc · OTC:VINC
Vincerx Pharma — Merger or Acquisition (January 2025)
23 slides from Vincerx Pharma's merger presentation, Jan 23, 2025
Slide 1: Investor Presentation January 23, 2025
Exhibit 99.1 ee Investor Presentation Li nvestor J January anuary 2 23, 3, 22025 025 PHARMA.
Slide 2: Forward-Looking Statements and Trademarks
FORWARD-LOOKING STATEMENTS AND TRADEMARKS FORWARD-LOOKING STATEMENTS No representations or warranties, expressed or implied are given in, or in respect of, this presentation. To the fullest extent permitted by law, in no circumstances will Oqory or Vincerx, or any of their respective subsidiaries, s
Slide 3: Important Notices
IMPORTANT NOTICES ADDITIONAL INFORMATION In connection with the proposed merger transaction between Oqory and Vincerx, Vincerx will file relevant materials with the Securities and Exchange Commission ( SEC ), including a proxy statement on Schedule 14A. A definitive proxy statement will be sent to h
Slide 4: Binding Term Sheet
BINDING TERM SHEET Vincerx Pharma, Inc. (“Vincerx”) and Oqory, Inc. (“Oqory”) entered into a Binding Term Sheet, as amended, pursuant to which Oqory would merge into Vincerx, Oqory stockholders would receive shares of Vincerx common stock in exchange for Oqory common stock, and options and other rig
Slide 5: Positioned to drive late-stage ADC innovation
Positioned to drive late-stage ADC innovation • • VersAptx Next-Generation Bioconjugation Platform Phase 3 Lead Asset: OQY-3258, TROP2 ADC • VIP943: CD123 ADC with Clinical Proof of Concept • ~150 breast cancer patients treated in Phase 1/2; Phase 3 trials underway in China • 1 CRL (33%) in high-ris
Slide 6: A Strategically Focused Pipeline with Potential for Expansion
A Strategically Focused Pipeline with Potential for Expansion PROGRAM INDICATION PHASE 1 PHASE 2 PHASE 3/ PIVOTAL 2L HR+/HER2- Breast Cancer OQY-3258/ESG401 TROP-2 ADC* 1L PD-L1 Negative TNBC POTENTIAL ADDITIONAL INDICATIONS • Non-small cell lung cancer (NSCLC) • Cervical cancer • Endometrial cancer
Slide 7: Transformative Deals Shaping the ADC Landscape
Transformative Deals Shaping the ADC Landscape $208m $1.8b $2b $43b $10b $4b Undisclosed April 2024 April 2024 November 2023 October 2023 Jan 2024 December 2023 October 2023 Merck acquires Genmab J&J acquired Pfizer acquired Abbvie acquired Merck GSK entered Abceutics agreed to ImmunoGen Ambrx Seage
Slide 8: TROP2 is Widely Expressed in Multiple Solid Tumors
T TROP2 ROP2 iis s W Widely idely E Expressed xpressed iin n M Multiple ultiple S Solid olid T Tumors umors TROP2 levels are higher in tumor issues vs baseline expression in corresponding normal tissues across TROP2 levels are higher in tumor issues vs baseline expression in corresponding normal tis
Slide 9: Differentiated Safety Profile and Compelling Efficacy
OQY-3258 Differentiated Safety Profile and Compelling Efficacy Gilead’s AZ/ Daiichi’s Merck’s OQY-3258 Trodelvy® Datroway® SAC-Tirumotecan (SG) (Dato-DxD) (SAC-TMT) Antibody Sacituzumab Sacituzumab Datopotamab Sacituzumab DAR 8 7.6 4 7.4 Linker Enzyme dependent pH-dependent Enzyme-dependent pH-depen
Slide 10: Clinical Study Design
OQY-3258 Clinical Study Design Phase 1b Dose Expansion 1 Phase 1a Dose Escalation Regimen: D1, 8, 15/28 IV n=40 n=115 18 mg/kg 12 mg/kg n=14 D1, 8, 15/28 16 mg/kg TNBC (≥3L) 14 mg/kg n=15 14 mg/kg 12 mg/kg 20 mg/kg 2 16 mg/kg n=39 TNBC (1L) Q3W 16 mg/kg 12 mg/kg 12 mg/kg n= 21 8 mg/kg HR+/ HER2- BC
Slide 11: Phase 1a/1b Patient Characteristics
OQY-3258 Phase 1a/1b Patient Characteristics 2 Patient Characteristics (Phase 1b) OQY-3258 (n=115) S St tu ud dy y p po op pu ulla at tiio on n c cllo os se elly y r re ef flle ec ct ts s Age, median (range) years 52 (33-73) k ke ey y d de em mo og gr ra ap ph hiic c a an nd d c clliin niic ca all c
Slide 12: OQY-3258 Demonstrates a Favorable Safety Profile
O OQY-3258 QY-3258 D Demonstrates emonstrates a a F Favorable avorable S Safety afety P Profile rofile ((Phase Phase 1 1b, b, n n=115) =115) Treatment-Emergent Adverse Effects (220%) (N=115) • The most common grade ≥3 White blood cell count decreased * The most common grade 23 Neutrophil count decre
Slide 13: Overview of Grade ≥3 Neutropenia
Overview of Grade ≥3 Neutropenia Patients with ≥2 occurrences of Grade ≥3 neutropenia n=11 • Only 17.5% of subjects at 16mg/kg D1,8,15/28d had ≥2 occurrence of Grade ≥3 neutropenia throughout the treatment. • No Grade ≥3 neutropenia caused permanent discontinuation and was manageable; subjects recov
Slide 14: Favorable and Differentiated Tolerability Compared with Competitors
OQY-3258 Shows Favorable and Differentiated Tolerability Compared with Competitors 70 63 OQY-3258 shows significantly 60 fewer treatment disruptions, 51.5 highlighting its improved 50 45 tolerability: 40 • Most common reason for 30 dose interruption was 25.4 22 neutropenia and 18.1 20 17.6 leukopeni
Slide 15: Safety Compared with Trodelvy (SG)
OQY-3258 Shows Favorable and Differentiated Safety Compared with Trodelvy (SG) All Grade Adverse Events (%) Grade 3-4 AEs (%) 100 60 94 88 90 86 49 50 78 80 76.5 73.9 41 70 62.6 40 36.5 59 60 31 50 30 26 40 20 29.6 30 11 17 20 9 10 12.2 7.8 4.3 10 3.5 2 0.9 0.9 0 0 Anemia Lymphopenia Leukopenia Neut
Slide 16: Safety Compared with Datroway (Dato-DxD)
OQY-3258 Shows Favorable and Differentiated Safety Compared with AZ/ Daiichi’s Datroway (Dato- DxD) All Grade Adverse Events (%) Grade ≥3 Adverse Events (%) 90 12 84.7 10.6 80 10 70 61.2 60 8 54.8 50 6 40 4.7 4 30 24.7 20 18.8 20 15.7 1.7 12.2 2 1.2 1.2 10 0.9 5.2 1.7 1.7 1.2 0 0 0 0 0 0 0 0 Oral Na
Slide 17: Safety Compared with Merck's SAC-tirumotecan
OQY-3258 Shows Favorable and Differentiated Safety Compared with Merck’s SAC-tirumotecan (SAC-TMT) All Grade Adverse Events (%) Grade 3-4 Adverse Events (%) 90 40 36.5 80 80 76.5 35 73.9 74 74 32 70 30 28 62.6 26 60 25 25 50 44 20 41 40 31 15 30 12 9 10 20 15.7 13 12.2 4.3 4 5 10 0.9 0.9 0 0 0 Anemi
Slide 18: Promising ORR Versus Combination Therapies in 1L TNBC
OQY-3258 Alone: Shows Promising ORR Versus Combination Therapies and Chemo Alone in 1L TNBC st (n=35) OQY-3258 TNBC 1 Line Confirmed Overall Response Rate (%) Stable Disease Partial Response Complete Response 90 80 79 80 70 58.9 60 52.7 50 42.6 40.8 40 30 20 10 OQY-3258 Progression Free Survival 0 O
Slide 19: Competitive Efficacy Outcomes in Late-Stage HR+/HER2- Breast Cancer
Competitive Efficacy Outcomes in Late-Stage HR+/HER2-Breast Cancer • Competitive Objective Response Best Change of Percentage in Target Lesion Size from Baseline N=58 Rate (ORR) of 34%, with 29% achieving confirmed complete or partial responses. • Disease Control Rate (DCR) of 78%. • Median (range)
Slide 20: Penetrated BBB with Efficacy in Brain Metastasis
OQY-3258: Penetrated BBB and Demonstrated Compelling Efficacy in Patients With Brain Metastasis B Br ra aiin n L Le es siio on n W Wa at te er rf fa allll C Ch ha an ng ge e Reduction In The Size Of The Intracranial Lesions In Patient #101009 Brain Metastases (n=17) Intracranial ORR: 41% T Ta ar rg
Slide 21: Next-Generation TROP2 ADC
OQY-3258 Next-Generation TROP2 ADC Innovative Breakthrough Efficacy Safety Phase 3 Linker Designation Awarded in China SN-38 toxin attached to Favorable Monotherapy efficacy Phase 3 trials in two safety/tolerability in 3 breast cancer metastatic breast cancer November 2024, for serum-stable linker w
Slide 22: Anti-TROP2 Phase Studies in PD-L1 negative 1L TNBC
Anti-TROP2 Phase 3 Studies in Metastatic / Unresectable, PD-L1 negative 1L TNBC Datroway OQY-3258 Dato-DxD Oqory AstraZeneca Company Phase Global Phase 3 Global Phase 3 TNBC TNBC Key Inclusion Criteria Metastatic/Unresectable Metastatic/Unresectable PD-L1 negative PD-L1 negative OQY-3258 Dato-DxD Tr
Slide 23: Anti-TROP2 Phase Studies in Advanced HR+/HER2- Breast Cancer
Anti-TROP2 Phase 3 Studies in Advanced, 1L+ HR+/HER2- Breast Cancer Trodelvy Datroway SAC-Tirumotecan OQY-3258 (SG) (Dato-DxD) (SAC-TMT) Oqory Gilead AstraZeneca Merck Company Phase 3 Phase 3 Phase 3 Phase Approved Global Study Global Study Global Study HR+/HER2- BCa HR+/HER2- BCa HR+/HER2- BCa HR+/
Vincerx Pharma — Merger or Acquisition (January 2025) on 6ix